FDA & Government News

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Share

The US FDA has conducted a meta-analysis of 91 placebo-controlled trials involving over 107,000 patients and found no correlation between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidal ideation or behavior. This finding has led to the conclusion that medications such as Saxenda, Wegovy, and Zepbound, previously labeled with warnings related to psychiatric risks, do not pose such threats. The FDA's request for new labeling aims to standardize the safety messages across all GLP-1 RAs, following ongoing evaluations and retrospective studies, confirming their safety for patients dealing with obesity and diabetes.

Original Source(s)

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

  • by Kathryn Wighton

  • January 13, 2026

  • 3 min

Related Content

Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC 

GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

Oxytocin’s Role in Obesity Management

Researchers review human data on oxytocin’s effects on appetite, satiety, and metabolic health